heavi
metal
notori
toxic
howev
medic
use
heaviest
stabl
element
bismuthwhich
util
antimicrobi
activ
low
collater
toxicitycan
trace
back
middl
age
base
increas
knowledg
characterist
bismuth
mani
compound
synthes
use
human
healthcar
particular
bismuth
citratebas
bi
cit
base
compound
clinic
use
worldwid
treat
peptic
ulcer
exhibit
promis
antivir
activ
two
bi
cit
base
drug
colloid
bismuth
subcitr
cb
denol
lizhudel
ranitidin
bismuth
citrat
rbc
tritec
pylorid
use
combin
antibodi
show
highest
therapeut
effici
helicobact
pylori
h
pylori
infect
due
import
cb
rbc
enorm
effort
made
elucid
structur
howev
structur
bismuth
citratebas
complex
complic
due
tendenc
polymer
empir
formula
cb
previous
given
k
nh
bi
oh
hcit
chang
polymer
bismuth
citrat
complex
latest
edit
merck
index
reflect
complic
polymer
featur
nine
bismuth
citrat
adduct
structur
character
xray
crystallographi
nmr
spectroscopi
compos
stabl
bismuth
citrat
dimer
unit
bi
cit
bi
addit
ohor
h
ligand
believ
bi
cit
bi
form
neg
charg
polymer
skeleton
bismuth
citrat
complex
aggreg
give
type
hybrid
metalorgan
framework
mof
howev
report
structur
bismuth
citrat
complex
base
crystal
obtain
neutral
ph
may
fail
reflect
structur
featur
bi
cit
base
complex
use
drug
sinc
bi
cit
base
drug
design
treat
diseas
stomach
physiolog
acid
close
ph
crystal
structur
bi
cit
base
complex
low
ph
therefor
precis
reflect
structur
featur
actual
therapeut
condit
order
studi
polymer
properti
degrad
pathway
bismuth
citrat
complex
report
structur
four
bi
cit
base
complex
form
via
assembl
bismuth
citrat
dimer
unit
bi
cit
bi
variou
amin
acid
condit
thermal
degrad
behavior
aminebi
cit
base
complex
structur
model
rbc
base
framework
one
complex
also
report
herein
bismuth
citrat
ethylenediamin
en
pyridin
py
ranitidin
ran
obtain
sigmaaldrich
use
directli
without
purif
solidst
c
nmr
spectra
record
varian
spectromet
equip
chemagnet
mm
doubl
reson
probe
mhz
use
cross
polarizationmag
angl
spin
cpma
spin
speed
khz
ms
contact
time
use
spatial
select
composit
puls
combin
convent
cp
puls
sequenc
order
effect
suppress
weak
signal
background
spin
modul
structur
tini
crystal
complex
crystal
size
mm
mm
mm
mm
mm
mm
mm
mm
mm
mm
mm
mm
respect
solv
use
oxford
diffract
xcalibur
nova
singl
crystal
diffractomet
cu
radiat
k
crystal
data
detail
refin
summar
tabl
support
inform
relev
bismuth
paramet
dreid
forc
field
gener
strategi
propos
univers
forc
field
uff
paramet
set
follow
harmon
bond
length
set
sp
hybrid
oxygen
atom
natur
bond
angl
set
van
der
waal
radiu
bismuth
taken
well
depth
kcalmol
dock
ranitidin
channel
form
bismuth
citrat
perform
ligandfit
adopt
dreid
forc
field
sampl
aminebi
cit
complex
esim
prepar
dissolv
suspens
bismuth
subcitr
ca
g
differ
dilut
amin
solut
ammonia
ethylenediamin
pyridin
ranitidin
ph
valu
solut
gradual
adjust
addit
dilut
hcl
allow
stand
overnight
filtrat
ph
valu
filtrat
adjust
ca
esim
experi
esim
experi
perform
lcq
spectromet
finnigan
corp
san
jose
ca
usa
sampl
infus
ion
produc
atmospher
pressur
ionizationesi
ion
sourc
sourc
temperatur
sheath
ga
flow
rate
lmin
potenti
kv
appli
probe
tip
cone
voltag
v
use
rang
da
bi
cit
base
complex
h
en
bi
cit
synthesi
rout
gener
crystal
data
complex
summar
scheme
tabl
support
inform
respect
addit
scheme
synthesi
bismuth
citratebas
complex
dilut
hcl
solut
ethylenediamin
bismuth
subcitr
white
precipit
form
remov
filtrat
upon
stand
filtrat
ph
room
temperatur
overnight
colorless
crystal
suitabl
xray
analysi
form
crystal
obtain
mother
liquor
stand
week
colorless
crystal
suitabl
xray
analysi
obtain
similar
fashion
use
pyridin
dissolv
bismuth
subcitr
complex
synthes
rout
mixtur
allow
crystal
ph
three
type
bismuth
citrat
dimer
bi
cit
bi
found
crystal
structur
ligand
coordin
bismuth
coordin
bond
length
differ
type
bi
cit
bi
summar
tabl
support
inform
dimer
ii
linearli
aggreg
along
c
axi
form
infinit
polyanion
concomitantli
link
dimer
iii
gener
twodimension
polymer
sheet
ac
plane
aggreg
dimer
iii
along
b
axi
link
polymer
sheet
result
threedimension
polymer
framework
figur
b
surprisingli
ethylenediamin
moieti
identifi
xray
crystallographi
howev
solidst
cpma
c
nmr
spectrum
show
strong
peak
ppm
assign
carbon
atom
ethylenediamin
presenc
singl
peak
indic
ethylenediamin
moieti
embed
disord
bismuth
citrat
channel
peak
ppm
assign
six
carbon
atom
bound
citrat
ligand
figur
structur
complex
compos
uniqu
bi
cit
bi
chlorid
ligand
bridg
two
adjac
dimer
result
infinit
polymer
sheet
bc
plane
figur
c
coval
crosslink
adjac
polymer
sheet
except
hydrogen
bond
hbond
electrostat
interact
suggest
complex
adopt
structur
five
differ
type
bi
cit
bi
observ
structur
complex
infinit
linear
polyanion
form
aggreg
dimer
ii
along
c
axi
adjac
polyanion
connect
dimer
iv
form
polymer
sheet
bc
plane
concomit
crosslink
dimer
ii
dimer
iii
dimer
iv
dimer
v
along
axi
lead
framework
pyridin
moieti
observ
clearli
caviti
figur
one
type
bi
cit
bi
observ
complex
two
deproton
hydroxyl
group
citrat
ligand
connect
adjac
dimer
unit
howev
contrast
adopt
architectureth
adjac
dimer
unit
crosslink
coordin
bond
along
b
axe
form
polymer
sheet
ab
plane
concomitantli
build
framework
via
assembl
along
c
axi
figur
e
ethylenediamin
could
identifi
crystal
structur
howev
element
analysi
show
presenc
ethylenediamin
complex
solidst
cpma
c
nmr
spectrum
two
peak
ppm
observ
confirm
presenc
ethylenediamin
embed
framework
figur
support
inform
citrat
anion
structur
complex
fulli
deproton
give
citrat
tetraanion
c
h
two
citrat
tetraanion
coordin
two
bi
cation
excess
neg
charg
polyanion
framework
balanc
h
nch
ch
nh
c
h
n
cation
common
structur
featur
suggest
lowmolecular
mass
molecul
ion
encapsul
either
diffus
process
electrostat
interact
similar
uptak
process
cation
small
molecul
zeolit
howev
size
level
protonat
insert
cation
also
affect
assembl
bismuth
citrat
dimer
shown
figur
support
inform
differ
shape
channel
caviti
form
framework
due
use
differ
type
cation
cation
fill
caviti
form
bismuth
citrat
skeleton
achiev
charg
balanc
acid
anoth
key
factor
affect
architectur
bismuth
citrat
complex
use
cation
h
nch
ch
nh
crystal
differ
ph
two
differ
type
framework
obtain
name
complex
growth
time
also
import
factor
convers
complex
observ
crystal
growth
time
extend
indic
thermodynam
stabl
form
bridg
citrat
anion
link
adjac
polymer
sheet
substitut
cl
complex
lose
polymer
linker
one
direct
result
breakup
framework
degrad
process
may
relev
far
pharmacokinet
behavior
bismuth
citratebas
drug
stomach
concern
thermogravimetricdifferenti
thermogravimetr
tgdtg
trace
complex
shown
figur
support
inform
observ
peak
dtg
curv
complex
togeth
accompani
weight
loss
tg
curv
indic
small
molecul
eg
water
releas
bismuth
citrat
framework
complex
lose
ca
weight
respect
indic
rel
encapsul
capac
sinc
previou
experi
demonstr
bismuth
citrat
polymer
skeleton
present
rbc
structur
model
rbc
base
framework
construct
shown
figur
ranitidin
molecul
readili
embed
caviti
perpendicular
bc
plane
hbond
probabl
form
ranitidin
molecul
bound
citrat
ligand
ranitidin
form
bond
citrat
dimer
distanc
respect
addit
sulfur
atom
ranitidin
form
hbond
water
molecul
coordin
bi
dimer
distanc
esim
tandem
mass
spectrometri
msm
recent
success
use
provid
definit
assign
fragment
molecular
speci
bismuth
compound
aqueou
solut
sinc
chemic
ioniz
process
mild
lead
signific
fragment
ion
present
solut
transfer
directli
sourc
studi
behavior
bi
cit
base
complex
aqueou
solut
sampl
bismuth
citrat
dissolv
differ
amin
prepar
esim
msm
data
record
incub
ph
figur
support
inform
esim
spectra
ammoniabi
cit
nh
bi
cit
pyridinebi
cit
pybi
cit
peak
mz
tabl
spectrum
ranitidinebi
cit
ranbi
cit
could
obtain
probabl
due
facil
ioniz
ranitidin
molecul
suppress
signal
intens
bismuth
citrat
howev
peak
correspond
bismuth
citrat
trimer
dimer
still
observ
although
esim
result
give
qualit
reflect
natur
bismuth
citrat
speci
solut
quantit
analysi
inappropri
ion
signal
reflect
extent
chemic
ioniz
well
rel
abund
bismuth
citrat
speci
seri
assum
proton
type
site
semiquantit
correl
abund
signal
intens
expect
certain
low
molecular
weight
bismuth
citrat
speci
dimer
higher
abund
high
molecular
weight
speci
trimer
tetram
observ
bismuth
citrat
oligom
correspond
tetram
mz
trimer
mz
dimer
mz
togeth
gradual
increas
abund
indic
bi
cit
base
poli
mer
degrad
high
molecular
weight
polymer
speci
low
molecular
weight
speci
eg
dimer
unit
solut
contrast
seri
degrad
peak
observ
aminebi
cit
absenc
incub
acid
ph
suggest
acid
play
essenti
role
decomposit
bi
cit
base
complex
xray
crystal
structur
four
bismuth
citratebas
complex
reveal
bismuth
citrat
dimer
unit
serv
basic
build
block
lead
complex
polymer
structur
regular
mesh
intern
caviti
composit
complex
framework
depend
size
level
proton
cation
ph
time
crystal
degrad
may
reflect
pharmacokinet
behavior
bismuth
citratebas
drug
polymer
mesh
caviti
complex
respons
abil
encapsul
small
molecul
demonstr
singl
crystal
xray
diffract
solidst
nmr
tgdtg
base
framework
structur
model
rbc
latest
bismuth
citrat
antiulc
drug
construct
show
ranitidin
molecul
insert
polymer
channel
insid
bismuth
citrat
framework
esim
studi
aminebismuth
citrat
acid
solut
depict
possibl
degrad
pathway
bismuth
citrat
skeleton
gastric
acid
ph
ie
bi
cit
base
drug
may
deposit
polym
ulcer
crater
degrad
low
molecular
weight
speci
either
action
gastric
acid
chloridewat
final
fulli
decompos
basic
unit
bi
cit
bi
subsequ
absorb
either
membran
receptor
feca
transport
via
iron
transport
pathway
base
studi
propos
possibl
pharmacokinet
pathway
bismuth
citratebas
drug
involv
degrad
bismuth
citrat
skeleton
polymer
framework
polymer
sheet
final
basic
dimer
unit
acid
condit
process
low
ph
may
allow
encapsul
drug
eg
ranitidin
releas
porou
bismuth
citrat
matrix
moreov
low
toxic
neg
charg
framework
regular
mesh
structur
suggest
bismuth
citratebas
polym
may
new
type
hybrid
metalorgan
framework
mof
potenti
applic
eg
drug
carrier
